Selinexor is an exportin‐1 (XPO1) inhibitor, and the CRISPR‐Cas9 system was used to show that resistance of cancer cells to this drug was because of mutations at the cysteine‐528 in the XPO1 gene.30 This evidence concerns the gene XPO1 and cancer.